Differential Prox-1 and CD 31 expression in mucousae, cutaneous and soft tissue vascular lesions and tumors by Reis, R. M. et al.
ARTICLE IN PRESS0344-0338/$ - se
doi:10.1016/j.pr
Correspondi
E-mail addre
1These authoPathology – Research and Practice 201 (2005) 771–776
www.elsevier.de/prpORIGINAL ARTICLE
Differential Prox-1 and CD 31 expression in mucousae, cutaneous and
soft tissue vascular lesions and tumors
Rui M. Reisa,1, Jorge S. Reis-Filhoa,b,1, Adhemar Longatto Filhoa,c,
Stanislav Tomarevd, Paula Silvae, Jose´ M. Lopese,f,
aLife and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal
bThe Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
cPathology Division, Adolfo Lutz Institute, Sa˜o Paulo, Brazil
dSection of Molecular Mechanisms of Glaucoma, Laboratory of Molecular and Developmental Biology,
National Eye Institute, Bethesda, MD, USA
eIPATIMUP – Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal
fMedical Faculty, Department of Pathology, University of Porto, Porto, Portugal
Received 26 April 2005; accepted 16 August 2005AbstractThe study of lymphatic vessels and lymphatic tumors has been hampered with difﬁculty due to the overlapping
morphological features between blood and lymphatic endothelial cells, as well as to the lack of speciﬁc lymphatic
endothelial markers. Over the last few years, lymphatic vessels and lymphangiogenesis have received great attention
owing to their putative implications in terms of metastatic dissemination and the promise of targets for
lymphangiogenic therapy. Prox-1 is a nuclear transcription factor that plays a major role during embryonic
lymphangiogenesis and is deemed to be a useful marker for differentiating lymphatic endothelial cells from the other
blood vessels endothelial cells. Here, we describe a double-immunostaining strategy for formalin-ﬁxed, parafﬁn-
embedded tissues that aims at evaluating the distribution of Prox-1 and CD 31 – a cytoplasmic pan-endothelial marker
– in a series of 28 mucousae, cutaneous and soft tissue vascular lesions and tumors, including hemangiomas,
lymphangiomas, lymphangiectasia, and Kaposi’s sarcomas. Our results showed that in non-lesional mucousae and
skin, Prox-1 decorated exclusively the nuclei of endothelial cells in lymphatic vessels. Prox-1 stained almost all the
benign lymphatic vascular lesions/tumors (91%) and was absent or only focally positive in 75% of blood vascular
tumors. CD 31 stained endothelial cells of blood vessels of superﬁcial and deep dermal plexuses, lymphatics, and all
blood vascular lesions/tumors. Kaposi’s sarcomas were all positive for both CD 31 and Prox-1 markers. In conclusion,
although Prox-1 expression in vascular lesions/tumors was not entirely restricted to tumors with known lymphatic
differentiation, CD 31/Prox-1 double-immunolabeling can be used as an adjunct marker to identify lymphatic vessels
in routinely processed formalin-ﬁxed, parafﬁn-embedded samples.
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The lymphatic network is a complex system composed
of variably sized vascular channels lined by specialized
endothelial cells, which drain interstitial ﬂuid and lymph
from peripheral tissues and return them to venous
system for recirculation [13,14,18,19]. The study of
lymphatic vessels and lymphatic tumors was long
forgotten due to the overlapping morphological features
between blood and lymphatic endothelial cells, as well as
to the lack of speciﬁc lymphatic endothelial markers
[13,14,18,19].
Recently, several new lymphatic markers have been
developed such as VEGFR-3 [4,6,13,14,18,19], LYVE-1
[6,9,13,14,18,19], podoplanin [4,13,14,18,19], D2-40 [10],
and Prox-1 [2,6,13–19,27,28]. Regardless of their sensi-
tivity for lymphatic endothelial cells, VEGFR-3, podo-
planin, and LYVE-1 fall short in speciﬁcity for these
cells [6,9,13,14,16,18,19,30]. VEGFR-3 is usually re-
stricted to lymphatic vessels in normal adult tissues, but
is re-expressed by blood endothelial cells in wound
healing and in tumor-induced neovessels [13,14,19,30].
LYVE-1 was originally reported to be speciﬁc for
lymphatic endothelial cells of cutaneous and solid
organs [9,13,14,18,19]; however, it is consistently ex-
pressed in endothelial cells of the hepatic sinusoids
[6,14]. Moreover, very recent studies demonstrated that
in experimental models of xenotransplanted tumors,
LYVE-1 also decorates capillaries in the alveolar walls,
as well as occasional lung arteries and veins [16]. Several
lines of evidence indicate podoplanin-speciﬁc expression
in lymphatic endothelial cells [4,13,14], but in vitro
models showed that only a fraction of podoplanin-
positive endothelial cells also co-express LYVE-1 [12].
D2-40 is a highly sensitive lymphatic marker and seems
to be useful for distinguishing vascular from lymphatic
vessels [10]. However, this marker cross-reacts with
leiomyosarcoma cells, malignant ﬁbrous histiocytoma
cells, and dermatoﬁbroma cells [10].
Prox-1, a homeobox gene cloned by homology with
the Drosophila gene prospero, is a nuclear transcription
factor that plays a major role during embryonic
lymphangiogenesis and in the differentiation of various
neuroectodermal structures [2,15,17,23,27,28]. Prox-1
knockout mice lack a terminally differentiated lympha-
tic system. Since Wigle and Oliver’s seminal study [27],
Prox-1 has been considered a speciﬁc and sensitive
lymphatic endothelial cell marker. At the mRNA level,
the only non-lymphatic endothelial cells expressing
Prox1 are found on the concave side of the cardiac
valves [23]. Interestingly, Prox-1 is the ﬁrst des-
cribed nuclear marker for lymphatic endothelial cells
[6,14,27,28].
We herein describe the distribution of Prox-1 in
normal skin and in a series of vascular lesions/tumors
by double-immunostaining with CD 31, a cytoplasmicpan-endothelial marker [24], and Prox-1, a nuclear
lymphatic endothelial cell marker.Material and methods
Patients and tumor samples
Formalin-ﬁxed, parafﬁn-embedded tissue blocks of
vascular lesions were retrieved from the pathology ﬁles
of the Hospital S. Joa˜o, Porto, Portugal, and from the
Institute of Molecular Pathology and Immunology of
University of Porto (IPATIMUP), Porto, Portugal. All
cases were independently reviewed by two pathologists
(JML and JSRF) and classiﬁed according to the new
World Health Organisation classiﬁcation [7,26]. Dis-
cordant cases were resolved on a multi-head microscope.
Only those cases in which an agreement was achieved
were included in the study. In 28 cases, both patholo-
gists agreed upon the diagnoses, including 9 capillary
hemangiomas, 3 cavernous hemangiomas, 1 spindle cell
hemangioma, 6 lymphangiomas, 3 cystic lymphangio-
mas, 1 lymphangioma circumscriptum, 1 lymphangecta-
sia, and 4 cutaneous Kaposi’s sarcomas. Formalin-ﬁxed,
parafﬁn-embedded tissue blocks of all cases were
available. Table 1 summarizes the clinicopathologic
features of the cases.Immunostaining procedures
The double-immunostaining technique was carried
out using a primary antibody raised against Prox-1 [2, 6]
and a commercial antibody against CD 31 (Neomarkers,
clone JC/70A, Freemont, CA, USA). Brieﬂy, sections
were immersed in antigen retrieval solution (DAKO,
Glostrup, Denmark) and microwaved at 600w for
20min. Sections were further incubated with Ultravision
block solution (Neomarkers, Freemont, CA, USA) for
10min at room temperature before incubation of 60min
at room temperature with the ﬁrst primary antibody
(Prox-1, 1:1000). Sections were sequentially washed in
PBS and incubated with biotinylated goat anti-poly-
valent immunoglobulin for 10min, streptavidin-perox-
idase for 10min, and developed with 3,30-diamino-
benzidine for 10min. Sections were also sequentially
incubated with goat serum for 20min, then with the
second primary antibody (CD 31, 1:25) for 60min at
room temperature, labeled with goat anti-mouse im-
munoglobulin for 30min, and then with APAAP (alka-
line phosphatase–antialkaline phosphatase complex) for
30min. Slides were developed with fast-red dye (Fast
Red Tablet, LabVision Co., Freemont, CA, USA) for
35–40min and mounted in aquatex medium (Merck,
Dermstadt, Germany).
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Table 1. Summary of the clinical pathologic features of the lesions
Case Gender Age Site Histopathological diagnosis
1 F 10 months Arm Capillary hemangioma
2 M 9 Face Capillary hemangioma
3 F 19 Finger Capillary hemangioma
4 M 2 Hand Capillary hemangioma
5 M 63 Oral cavity Capillary hemangioma
6 F 15 Shoulder Capillary hemangioma
7 F 63 Skin Capillary hemangioma
8 M 1 Thorax Capillary hemangioma
9 M 11 Face Capillary hemangioma
10 F 5 Forearm Cavernous hemangioma
11 F 33 Knee Cavernous hemangioma
12 F 44 Neck Cavernous hemangioma
13 M 41 Gum Spindle cell hemangioma
14 M 51 Face Lymphangioma
15 F 10 months Mediastinum Lymphangioma
16 F 4 Neck Lymphangioma
17 M 7 Thigh Lymphangioma
18 F 21 Vulva Lymphangioma
19 M 2 Tongue Lymphangioma
20 M 2 Axilla Cystic lymphangioma
21 M 5 Axilla Cystic lymphangioma
22 M Newborn Neck Cystic lymphangioma
23 F 53 Vulva Lymphangioma circumscriptum
24 F 47 Oral cavity Lymphangectasia
25 M 22 Face Kaposi’s sarcoma
26 F 68 Thigh Kaposi’s sarcoma
27 F 42 Multifocal Kaposi’s sarcoma
28 M 48 Multifocal Kaposi’s sarcoma
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For the immunohistochemical analysis, the expression
of CD 31 and Prox-1 was independently evaluated by
two pathologists (JML and JSRF) in a blinded fashion
and not being aware of the histopathological diagnosis.
A semiquantitative analysis for the distribution of both
markers in endothelial cells was performed according to
the following scoring system: negative (): absence of
expression; focal positive (7): expression in up to 10%
of the vascular structures; positive (+): expression in
more than 10% of vascular structures.
Positive reactions were assessed in hot spot areas in
which proliferating vascular structures were present and
stained. Negative controls of reactions were performed
by substituting the immune sera with non-immune
rabbit serum or negative control rabbit IgG or by
omitting the primary antibodies. As Prox-1 is consis-
tently expressed in retinal neuroepithelial cells [25],
sections of normal human retina were used as positive
controls, whereas for CD 31, sections of a lymphangio-
ma of vulvae were used. All controls were satisfactorily
stained in each slide run.Results
In the skin/mucousae adjacent to the vascular lesions/
tumors, Prox-1 stained only the nuclei of endothelial
cells in vascular structures with very thin walls
comprising only endothelial cells, without red blood
cells in their luminal spaces, consistent with lymphatic
vessels [22]. Double staining disclosed a clear differential
pattern when comparing blood-type with lymphatic-
type vessels: both types of vessels showed endothelial
cell cytoplasm stained with fast-red (CD 31), whereas
only lymphatic type vessels disclosed endothelial cell
nuclei stained with brown DAB (Prox-1) (Fig. 1A).
Blood vessels with morphologically evident pericytic or
smooth muscle layers, epidermal, squamous epithelial,
appendageal, and dermal or corion structures were
consistently negative for Prox-1. CD 31 strongly
decorated endothelial cells of blood vessels of the
superﬁcial and the deep dermal plexus. In intra-ocular
tissues, used as a control, PROX-1 decorates the nuclei
of the inner nuclear layer of the retina (Fig. 1B) whereas
none of the endothelial cells in the intra-ocular vessels
stained for Prox-1 (Fig. 1B). This was expected, as
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Fig. 1. Appearance of Prox-1 and CD 31 immunohistochem-
istry in normal controls and vascular lesions. (A) Prox-1
positivity (brown) in endothelial nuclei of lymphatics and
negativity in blood vessels of oral mucosae. Both types of
vessel show endothelial cytoplasmic (red) CD 31 positivity
(Double Prox-1/CD 31 immunostaining). (B) Prox-1 expres-
sion (brown) in the nuclei of the inner nuclear layer of the
retina. Of note is the absence of Prox-1 expression in
endothelial cells (Single Prox-1 immunostaining, counter-
stained with hematoxylin). (C) Lymphangioma showing
endothelial cells with Prox-1 nuclear (brown) and CD 31
cytoplasmic (red, inset) positivity (Double Prox-1/CD 31
immunostaining). (D) Hemangioma showing CD 31 endothe-
lial cytoplasmic positivity (red) and absence of nuclear Prox-1
reactivity (Double Prox-1/CD 31 immunostaining). (E) Spin-
dle cell hemangioma nuclear Prox-1 (brown) and cytoplasmic
CD 31 (red) co-expression in tumor cells of the spindle cell
component. The hemangiomatous component shows CD 31
endothelial cytoplasmic positivity (red) and absence of nuclear
Prox-1 reactivity (Double Prox-1/CD 31 immunostaining). (F)
Kaposi’s sarcoma showing nuclear Prox-1 (brown) and
cytoplasmic CD 31 (red) co-expression in tumor cells (Double
Prox-1/CD 31 immunostaining).
Table 2. Expression of Prox-1 and CD 31 in vascular lesions
and tumors
Case Histopathological diagnosis CD 31 Prox-1
1 Capillary hemangioma + 
2 Capillary hemangioma + +
3 Capillary hemangioma + 
4 Capillary hemangioma + +
5 Capillary hemangioma + 
6 Capillary hemangioma + 
7 Capillary hemangioma + 
8 Capillary hemangioma + 
9 Capillary hemangioma + 7
10 Cavernous hemangioma + +
11 Cavernous hemangioma + 
12 Cavernous hemangioma + 7
13 Spindle cell hemangioma + +a
14 Lymphangioma + 
15 Lymphangioma + +
16 Lymphangioma + +
17 Lymphangioma + +
18 Lymphangioma + +
19 Lymphangioma + +
20 Cystic lymphangioma + +
21 Cystic lymphangioma + +
22 Cystic lymphangioma 7 +
23 Lymphangioma circumscriptum + +
24 Lymphangectasia 7 7
25 Kaposi’s sarcoma + +
26 Kaposi’s sarcoma + +
27 Kaposi’s sarcoma + +
28 Kaposi’s sarcoma + +
, Absence of expression; 7, up to 10% of positive cells; +, more
than 10% of positive cells.
aPositivity was restricted to the spindle cell component. Dilated
blood vessels were lined by Prox-1-negative endothelial cells.
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compartment.
Prox-1was observed in all but one lymphatic-derived
tumors 10/11 (91%) (Fig. 1C, Table 2). Prox-1 was
negative in 7/12 (58%) blood vessel tumors (Fig. 1D,
Table 2). The positive blood vessels tumors were 3
capillary hemangiomas and 2 cavernous hemangiomas
(Table 2). The spindle cell hemangioma (Fig. 1E)
showed a peculiar distribution of CD 31/Prox-1: spindle
cells were consistently positive for both markers,whereas endothelial cells lining dilated vessels were
negative for Prox-1, but positive for CD 31, thus
reﬂecting a complex admixture of different cell types
in these tumors. On the other hand, in lesions with
known lymphatic histogenesis/differentiation, CD 31
showed moderate to strong staining in most of the cases,
except in 2 lymphatic-derived lesions (cases 22 and 24),
which showed less than 10% of positive cells (Table 2).
Kaposi’s sarcomas were strongly positive for both CD
31 and Prox-1 markers (Fig. 1F, Table 2).Discussion
Prox-1 has now been established as an essential fate-
determining factor for lymphatic endothelial cell ex-
pression in the developing vessels. Rediscovering the
lymphatic system has had a signiﬁcant impact on cancer
therapy, namely prompting the development of speciﬁc
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primary site through lymphatic conduits. For this
particular purpose, the identiﬁcation of speciﬁc lympha-
tic markers is of utmost importance [1,11,14,21,22].
Differentiating blood from lymphatic vessels is
particularly difﬁcult in certain circumstances even for
experienced pathologists. Morphological characteristics
of endothelial cells, particularly under neoplastic condi-
tions, are not clear-cut and do not allow for a proper
distinction between blood and lymphatic vessels. This
becomes even more complicated in vascular tumors and
vascular malformations, which happen to be lesions of
complex histogenesis comprising both blood and lym-
phatic vessels [29].
As Prox-1 is also expressed in some non-endothelial
cells such as hepatocytes, bile ductum epithelium,
pancreatic epithelium, central nervous system, lens,
retina, and cardiomyocytes in avian and murine
embryos [22,29], a CD 31/Prox-1 double-immunolabel-
ing method proved cautious and very useful to identify
lymphatic vessels, in particular in reactive and neoplas-
tic lesions, where blood and lymphatic vessels frequently
harbor morphological and protein regulation different
from that of their non-neoplastic counterparts [8,20,29].
The importance of vascular studies in neoplasias has
been intensively studied [5]. Angiogenesis and lymphan-
giogenesis are crucial for the understanding of tumor
biology and for designing potential cancer preventive
and therapeutic measures, since both vasculature
systems probably cross talk with each other and share
common signaling factors [1].
We present some data concerning the distribution of
Prox-1 in vascular lesions and tumors. Twenty out of 28
cases were positive for Prox-1 (71.4%). Most impor-
tantly, 9 out of 10 lesions with known lymphatic
differentiation were positive for this marker
(sensitivity ¼ 90%). Wilting et al. [29] have studied the
expression of Prox-1 and CD 31, among other markers,
to differentiate blood and lymphatic vessels using
immunoﬂuorescent markers in a series composed by
fetal intestine, skin lymphedema, hemangioma, and
lymphangioma. Particularly in hemangiomas, they
found the co-expression of CD 31 and CD 34 (a marker
frequently expressed in blood vessels), but not Prox-1.
Conversely, they found Prox-1, CD 31, and VEGFR-3
expression, but not CD 34 in lymphangiomas. In our
series, Prox-1-positive endothelial cells were observed in
3 capillary and 2 cavernous hemangiomas. Two conclu-
sions may be drawn from these ﬁndings: (i) gene
expression patterns of vascular tumors are more
complex than previously appreciated and (ii) although
remarkably sensitive, Prox-1 is not entirely restricted to
lymphatic neoplastic vessels. Therefore, caution should
be exercised when using Prox-1 as a lymphatic marker in
this context. In fact, in our view, Prox-1 should rather be
used as a nuclear lymphatic marker in conjunction withother cytoplasmic antibodies for identifying lymphatic
differentiation in vascular neoplasms. However, Prox-1
can be reliably used for the identiﬁcation of lymphatic
vessels in non-vascular tumor and reactive/inﬂamma-
tory samples.
The histogenesis/differentiation displayed by neoplas-
tic endothelial cells of Kaposi’s sarcomas is still a
contentious issue [3,8]. In the present study, Kaposi’s
sarcomas were consistently positive for both CD 31 and
Prox-1. Our results are in agreement with those of
previous reports on the lymphatic nature of Kaposi’s
sarcomas using other lymphatic markers, including
VEGFR-3, LYVE-1, and D2-40 [3,8,10,31]. Taken
together, these results demonstrate that Kaposi’s sarco-
mas should be perceived as tumors with lymphatic vessel
differentiation.
The spindle cell hemangioma showed a characteristic
distribution, exhibiting positivity for Prox-1 in the
spindle cell areas and no staining for this marker in
the nuclei of endothelial cells lining dilated blood
vessels. As the distribution of Prox-1/CD 31 staining
in the spindle cell component of the spindle cell
hemangioma and Kaposi’s sarcomas is remarkably
similar, our double-immunostaining method cannot be
used for differentiating these two lesions. On the other
hand, the similar reactivity pattern does suggest that the
spindle cell component of both, Kaposi’s sarcoma and
spindle cell hemangioma, may harbor features of early
lymphatic differentiation.
In summary, our results demonstrate that Prox-1
staining is a feasible tool to identify lymphatic vessels in
routinely processed formalin-ﬁxed, parafﬁn-embedded
samples. In addition, CD 31/Prox-1 double-immunola-
beling proved useful owing to their high sensitivity of
these antibodies as markers of blood and lymphatic
endothelial cells, respectively. Prox-1 expression in
vascular lesions/tumors was not entirely restricted to
tumors with known lymphatic differentiation. This fact
opens interesting ﬁelds for further research on the
upregulation of Prox-1 in neoplastic scenario. Finally,
our results support the suggestion of the lymphatic
nature of Kaposi’s sarcomas [3].References
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